Integra Lifesciences Holdings Corp

IART

Equity

ISIN US4579852082 / Valor 912247

NASDAQ (2024-09-18)

USD 17.53+2.16%

Integra Lifesciences Holdings Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Integra Lifesciences Holdings Corp is a global leader in neurosurgery, offering a wide range of products and solutions for dural access and repair, cerebral spinal fluid management, and neuro-critical care. The company recently acquired Acclarent, Inc., a pioneer in ear, nose, and throat surgical interventions, which has expanded Integra's market-leading brands and provided immediate scale and accretive growth through a dedicated sales channel.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Integra Lifesciences Holdings Corp reported second quarter 2024 revenues of $418.2 million, marking a 9.7% increase on a reported basis and a 2.3% increase on an organic basis compared to the prior year. Excluding the Boston facility, organic growth was 0.3%.

Earnings Per Share

For the second quarter of 2024, Integra Lifesciences Holdings Corp reported GAAP earnings per diluted share of $(0.16), a decrease from $0.05 in the prior year. Adjusted earnings per diluted share were $0.63, compared to $0.71 in the previous year.

Segment Performance

In the second quarter of 2024, the Codman Specialty Surgical segment, which accounts for approximately 70% of revenues, reported total revenues of $301.8 million. This represents a reported growth of 11.3% and organic growth of 0.9% compared to the same period in 2023.

Net Income

Integra Lifesciences Holdings Corp reported a GAAP net loss of $(12.4) million for the second quarter of 2024, compared to a GAAP net income of $4.2 million in the prior year. Adjusted net income for the quarter was $49.0 million, down from $57.4 million in the previous year.

2024 Outlook

For the full year 2024, Integra Lifesciences Holdings Corp updated its revenue guidance to a range of $1.609 billion to $1.629 billion and adjusted EPS guidance to a range of $2.41 to $2.57 per share. This update reflects temporary shipping holds and significant investments in quality system and GMP compliance improvements.

Summarized from source with an LLMView Source

Key figures

-55.3%1Y

-74.8%3Y

-71.3%5Y

Performance

47.2%1Y

39.0%3Y

37.6%5Y

Volatility